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Abstract
Certain host genetic variants, especially in the human leucocyte antigen (HLA) region, are
associated with different progression of HIV-1-induced diseases and AIDS. Long term non
progressors (LTNP) represent only the 2% of infected patients but are especially relevant
because of their efficient HIV control. In this work we present a global analysis of genetic
data in the large national multicenter cohort of Spanish LTNP, which is compared with sero-
negative individuals and HIV-positive patients. We have analyzed whether several single-
nucleotide polymorphisms (SNPs) including in key genes and certain HLA-A and B alleles
could be associated with a specific HIV phenotype. A total of 846 individuals, 398 HIV-1-
positive patients (213 typical progressors, 55 AIDS patients, and 130 LTNPs) and 448 HIV-
negative controls, were genotyped for 15 polymorphisms and HLA-A and B alleles. Signifi-
cant differences in the allele frequencies among the studied populations identified 16 LTNP-
associated genetic factors, 5 of which were defined for the first time as related to LTNP phe-
notype: the protective effect of HLA-B39, and the detrimental impact of HLA-B18, -A24,
-B08 and –A29. The remaining eleven polymorphisms confirmed previous publications,
including the protective alleles HLA-B57, rs2395029 (HCP5), HLA bw4 homozygosity,
HLA-B52, HLA-B27, CCR2 V64I, rs9264942 (HLA-C) and HLA-A03; and the risk allele HLA
bw6 homozygosity. Notably, individual Spanish HIV-negative individuals had an average of
0.12 protective HLA alleles and SNPs, compared with an average of 1.43 protective alleles
per LTNP patient, strongly suggesting positive selection of LTNP. Finally, stratification of
LTNP according to viral load showed a proportional relationship between the frequency of
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protective alleles with control of viral load. Interestingly, no differences in the frequency of
protection/risk polymorphisms were found between elite controllers and LTNPs maintaining
viral loads <2.000 copies/mL throughout the follow-up.
Introduction
The host genetic determinants influencing progression of HIV infection to disease and
acquired immunodeficiency syndrome (AIDS) have been extensively studied in several
cohorts of LTNP individuals of Caucasian ancestry. This is the case of several allelic variants in
genes encoding the HIV-1 co-receptors and their ligands, such as CCR2 and CCR5, certain
cytokines such as IL10, co-factors and interferon-induced proteins [1–9]. Among these host
factors, the human major histocompatibility HLA class I complex has the strongest influence
on HIV-1 progression. Thus, the HLA-B�57 and HLA-B�27 alleles are strongly associated with
delayed HIV disease progression [10, 11] whereas HLA-B�35 is associated with accelerated
progression to AIDS [12, 13]. In addition, control of viremia and protection from AIDS is
associated with HLA bw4 allelic grouping homozygosity [14]. More recent studies identified
allelic variants associated with control of HIV-1 replication in HLA-C and HLA complex P5
(HCP5) [15, 16], which in turn is in tight linkage disequilibrium with the HLA-B�5701 allele
[17]. Studies based on genome-wide association strategies identified novel genetic variants
associated with delayed disease progression [18–25], most of them within the HLA complex
[19, 23, 24].
These data suggest that disease progression and HIV-1 replication is controlled by several
loci of the human genome. However, known genes affecting disease progression and their vari-
ants do not fully explain the highly variable course of HIV-1 infection or its pathogenic mecha-
nisms. The aim of the present study is to characterize genetically the large Spanish HIV LTNP
cohort and to identify novel associations with disease control, employing a multicenter cohort
of 398 Spanish HIV-1 positive patients compared with a control population of 448 healthy
Spaniards. By comparing the genotype distribution of several SNPs as well as the frequency of
HLA-A and HLA-B alleles, the present work proposes 5 novel HLA class I alleles related to
maintenance of the LTNP status [defined as HIV-infected patients that maintain CD4-lym-
phocytic counts above 500 cells/uL for at least ten years in the absence of antiretroviral treat-
ment (ART). Viral load is usually low in this group of patients (<10.000 RNA copies/ml, as
defined in the Spanish LTNP-Cohort)]and confirms the role of known genetic markers associ-
ated with control of HIV-1 replication. The analysis of these genetic traits stratified by different
phenotypes within LTNP patients, showed a differential effect according to the LTNP subcate-
gory, evidencing the necessity to clearly define the LTNP condition in case/control association
studies. In addition to supporting the category of EC with undetectable viral load (VL), we pro-
pose the use of a regularly maintained VL below the limit of 2,000 copies/mL as a new marker
of profound and stable LTNP status.
Materials and methods
Patient samples
A total of 448 healthy bone marrow donors (HD), as well as 398 HIV-1 infected patients, com-
prising 55 AIDS patients, 213 typical progressors (TP) and 130 LTNP, were included in the
study. The uninfected individuals were healthy Spanish donors from the Blood Transfusion
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Centre of the Community of Madrid, Spain, and are representative of the Spanish population
[26]. All HIV-1 infected patients belonged to different cohorts of patients with samples stored
at the HIV BioBank (Gregorio Marañón University Hospital, Madrid, Spain), which is inte-
grated in the Spanish AIDS research network (RIS) [27] All the samples were collected from
2004 to 2007. CoRIS, the RIS cohort of adults with HIV infection, was launched in 2004 [28].
CoRIS is an open multicenter cohort of patients that are over 13 years of age and newly diag-
nosed with HIV infection in the participating hospital or treatment center they attend for the
first time, and that are naïve to antiretroviral treatment. This study was reviewed and approved
by the institutional Ethics committee for research and clinical trials" (CEIC) from Instituto de
Salud Carlos III. All patients signed and informed consent to include their blood samples for
scientific research including genetic studies in the Biobank of the Spanish AIDS Research Net-
work. The information is subject to internal quality controls; once every 2 years, information
on 10% of the cohort is audited by an external agency.
A total of 55 AIDS and 213 TP patients come from CoRIS. The AIDS group includes naïve
patients late diagnosed after attending a participating center for the first time; the TPs are
HIV-1 infected patients with CD4+ cell loss between 50–100 cells/μl per year. The 130 LTNP
patients belong to the Spanish Cohort of LTNP (LTNP-RIS), a cohort similarly managed as
above, and were naïve patients who have CD4+ T cell counts over 500/μl and VL< 10,000 cop-
ies/mL without antiretroviral treatment for at least 10 years after HIV diagnosis. The prototyp-
ical recruited HIV-1 infected individuals were male intravenous drug users of Spanish origin
(Table 1).
Based on specific clinical data, including VL and time after seroconversion, we defined sev-
eral LTNP subcategories. Thus, three mutually exclusive subcategories of LTNP have been ana-
lyzed, including ExLTNP, who are patients that lost LTNP status after at least 10 years after
HIV-1 diagnosis; viremic non-controller LTNP (LTNP-N), who are LTNP maintaining detect-
able VL> 50 up to 10,000 copies/mL throughout the follow-up; and EC, defined as HIV-1
infected individuals with undetectable VL during follow-up. In addition, LTNP-C controllers
includes a subgroup of LTNP-N maintaining VL <2,000 copies/mL throughout the follow-up;
this subcategory includes all EC but also those LTNP-N with low VL. Blood samples were pro-
cessed following standard procedures [29] and frozen immediately after their processing.
Peripheral blood mononuclear cells were obtained from blood of all subjects included in the
study and DNA was extracted.
Sample genotyping
Genomic DNA was used for genotyping. Most SNP tested were typed using TaqMan SNP gen-
otyping assay following manufacturer’s procedures and standardized protocols (Applied Bio-
systems), except for rs333 (CCR5-Δ32) and rs1801157 (SDF-1), which were determined by real
time PCR employing the primers and probes described in S1 Table. The TaqMan Universal
PCR Master Mix and standard thermocycling conditions were employed for all polymor-
phisms on an ABI PRISM 7000 system, and allele calling was performed using AutoCaller SDS
Software v 1.2.3. (Applied Biosystems).
HLA typing
Two-digit HLA-A and HLA-B typing was carried out using sequence-specific oligonucleotide
(SSO) hybridization following manufacturer’s procedure and standardized protocol (RELI
SSO HLA Typing Kit, Invitrogen). Genomic DNA was amplified using locus-specific primers
flanking exons 2 and 3 of the HLA class I genes. The PCR products were hybridized to an
array of immobilized sequence-specific oligonucleotide probes. The probe-bound amplified
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product was detected by a color formation assay. All assays were automated using the Auto-
RELI 48 Instrument (Dynal Biotech). The HLA-B alleles were grouped into HLA bw4 and
HLA bw6 epitopes according to the official page of HLA nomenclature [30].
Statistical analysis
Genotype frequency comparisons between groups were performed by two-tailed Fisher’s exact
test in R package for each SNP (p-values of 2x3 tables). The frequency of HLA alleles was also
analyzed by two-tailed Fisher’s exact test in R package (p-values of 2x2 tables). The results
were corrected for multiple hypothesis testing to control the Benjamini–Hochberg false dis-
covery rate (FDR) at a significant threshold of 0.1 to compare LTNP with different control
populations (q-value). A similar correction was made to compare different subcategories of
LTNP individuals with control populations, using a significant threshold of 0.05 (q-value).
Results
SNP and polymorphisms associated with the Spanish long term non
progressors cohort phenotype
The individuals included in the analysis were genotyped for 14 different SNP and the CCR5-
Δ32 polymorphism. Eleven out of 14 SNP did not differ significantly between LTNP and
groups of healthy donors, AIDS patients and typical progressors (Table 2).
However, a significant difference in the genotype distribution was identified in 3 SNP
(HCP5, CCR2 and 5’HLA-C) (Table 2). In the case of HCP5, a clearly higher frequency of the
genotype TG was found in LTNP compared with HD and TP groups, and less significant with
AIDS patients (Table 2). The differences in the GA/AA genotype distribution of the SNP caus-
ing the V64I mutation in CCR2 (HIV-1 co-receptor that is associated with protection [3]) were
highly significant when comparing LTNP with HD. Regarding the Δ32 deletion of the CCR5
HIV-1 co-receptor locus that is associated with delayed HIV disease progression [1, 2, 5], a
higher frequency of the protective WT/Δ32 genotype was observed in LTNP than in the AIDS
group, but these differences did not reach statistical significance after FDR correction. The var-
iant -35C/T located 35 kb upstream of the HLA-C locus has been associated with delayed HIV
disease progression in infected patients [16]. Accordingly, a significantly higher frequency of
the CC and CT genotypes was found in Spanish LTNP compared with TP (Table 2). Therefore,
our data confirm the association of HCP5, CCR2 and 5’HLA-C SNPs to LTNP phenotype.
Table 1. Summary of epidemiological characteristics of HIV-1 infected patients included in the analysis.
Characteristic TP (n = 213) AIDS (n = 55) LTNP (n = 130)
Age upon admission, mean (min-max) 39 (17–69) 42 (22–61) 48 (30–76)
Unknown, n 27
Country of origin, % Spain 100 100 77.0
Unknown 23.0
Sex, % Male 69.0 74.5 53.8
Female 31.0 25.5 26.2
Unknown 20.0
Risk group, % Intravenous drug user 68.1 60.0 64.6
Homosexual/bisexual 9.4 14.5 5.4
Heterosexual 16.4 16.4 13.1
Others (transfusion, etc.) 3.3 7.3 2.3
Unknown 2.8 1.8 14.6
https://doi.org/10.1371/journal.pone.0220459.t001
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Table 2. Genotype distribution of different single nucleotide polymorphisms in distinct groups of HIV patients and in healthy donors.
SNP Group (n) Genotype distribution p-valuea FDRb
n % n % n %
CCR5–2459 (G/A) GG GA AA
rs1799987 HD (122) 25 20.5 53 43.4 44 36.1 0.0236 ns
LTNP (127) 33 26.0 68 53.5 26 20.5 - -
SDF-1 3'UTR 801 (G/A) GG GA AA
rs1801157 HD (158) 98 62.0 49 31.0 11 7.0 ns ns
LTNP (117) 73 62.4 38 32.5 6 5.1 - -
RANTES -403 (G/A) GG GA AA
rs2107538 HD (164) 114 69.5 44 26.8 6 3.7 ns ns
AIDS (55) 34 61.8 18 32.7 3 5.5 ns ns
TP (212) 145 68.4 58 27.4 9 4.2 ns ns
LTNP (130) 90 69.2 37 28.5 3 2.3 - -
CD32α +494 (A/G) AA AG GG
rs1801274 HD (159) 42 26.4 86 54.1 31 19.5 ns ns
AIDS (55) 12 21.8 31 56.4 12 21.8 ns ns
TP (213) 42 19.7 111 52.1 60 28.2 ns ns
LTNP (124) 32 25.8 61 49.2 31 25.0 - -
Tsg101–517 (C/T) CC CT TT
rs1857909 HD (259) 209 80.7 49 18.9 1 0.4 ns ns
AIDS (55) 44 80.0 10 18.2 1 1.8 ns ns
TP (213) 177 83.1 35 16.4 1 0.5 ns ns
LTNP (130) 115 88.5 15 11.5 0 0 - -
Rab27a 3'UTR (C/T) CC CT TT
rs1050931 HD (248) 161 64.9 76 30.6 11 4.4 ns ns
AIDS (54) 36 66.7 16 29.6 2 3.7 ns ns
TP (211) 144 68.2 57 27.0 10 4.7 ns ns
LTNP (130) 87 66.9 39 30.0 4 3.1 - -
Rggta (G/A) GG GA AA
rs729421 HD (177) 68 38.4 89 50.3 20 11.3 ns ns
AIDS (55) 16 29.1 29 52.7 10 18.2 ns ns
TP (213) 80 37.6 102 47.9 31 14.6 ns ns
LTNP (111) 52 46.8 59 53.2 18 16.2 - -
αCatenin 3'UTR (G/T) GG GT TT
rs288039 HD (163) 84 51.5 66 40.5 13 8.0 ns ns
AIDS (55) 26 47.3 22 40.0 7 12.7 ns ns
TP (212) 114 53.8 82 38.7 16 7.5 ns ns
LTNP (69) 40 58.0 23 33.3 6 8.7 - -
αCatenin 3'UTR (A/T) AA AT TT
rs3749663 HD (260) 136 52.3 102 39.2 22 8.5 ns ns
AIDS (55) 25 45.5 23 41.8 7 12.7 ns ns
TP (212) 114 53.8 81 38.2 17 8.0 ns ns
LTNP (129) 71 55.0 47 36.4 11 8.5 - -
αCatenin intron (C/T) CC CT TT
rs700626 HD (168) 92 54.8 66 39.3 10 6.0 ns ns
LTNP (69) 39 56.5 24 34.8 6 8.7 - -
HCP5 3'UTR (T/G) TT TG GG
(Continued)
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Genotype distribution of significant SNP and CCR5-Δ32 polymorphism in
distinct subcategories of the Spanish LTNP cohort
As described in Methods section LTNP were stratified according to VL into 4 subcategories,
ExLTNP, viremic non controllers LTNP-N, controllers LTNP-C and elite controllers EC (Fig
1A), and the genotype frequencies of the relevant genetic factors were determined (i.e. HCP5,
CCR2 and 5’HLA-C SNPs). The results confirmed the protective nature of the HCP5 and
CCR2 genotypes, as they were more frequent in most subcategories of LTNP, especially in
those subcategories with the lowest VL, the LTNP-C and the EC, than in the other HIV-
infected or HD populations (Table 3). For a summary and statistics see Table 4. Actually,
HCP5 and CCR2 SNP frequencies were gradually increased within LTNP subcategories in an
inverse correlation with VL (framed data in Table 3), with percentages of HCP5 and CCR2
favorable genotypes peaking at the EC population with undetectable VL (Fig 1B). For a sum-
mary and statistics see Table 4.
The enrichment of the HCP5 and CCR2 favorable genotypes in EC-LTNP with undetectable
VL was somehow expected. However, it is very noticeable that the LTNP-C controllers, whose
VL are always maintained below 2,000 copies/mL, are also very significantly endowed with
Table 2. (Continued)
SNP Group (n) Genotype distribution p-valuea FDRb
n % n % n %
rs2395029 HD (254) 245 96.5 9 3.5 0 0 3.94x10-8 1.5x10-6
AIDS (55) 51 92.7 4 7.3 0 0 0.0189 ns
TP (213) 191 89.6 22 10.4 0 0 0.0044 0.057
LTNP (128) 100 78.2 28 21.8 0 0 - -
CCR2-V64I +190 (G/A) GG GA AA
rs1799864 HD (262) 220 84.0 40 15.3 2 0.8 0.0097 0.092
AIDS (55) 44 80.0 10 18.2 1 1.8 ns ns
TP (212) 163 76.9 46 21.7 3 1.4 ns ns
LTNP (129) 92 71.3 34 26.4 3 2.3 - -
CCR5 Δ32 (WT/Δ32) WT/WT WT/Δ32 Δ32/Δ32
rs333 HD (246) 204 82.9 40 16.3 2 0.8 ns ns
AIDS (55) 50 90.9 5 9.1 0 0 0.0245 ns
TP (213) 173 81.2 40 18.8 0 0 ns ns
LTNP (129) 98 76 31 24.0 0 0 - -
5'HLA-C (C/T) CC CT TT
rs9264942 AIDS (55) 16 29.1 22 40.0 17 31.9 ns ns
TP (212) 41 19.3 104 49.1 67 31.6 0.0045 0.057
LTNP (128) 36 28.1 71 55.5 21 16.4 - -
IL-10–592 (C/A) CC CA AA
rs1800872 HD (250) 142 56.8 87 34.8 21 8.4 ns ns
AIDS (54) 30 55.6 17 31.5 7 13.0 ns ns
TP (208) 113 54.3 85 40.9 10 4.8 ns ns
LTNP (125) 71 56.8 49 39.2 5 4.0 - -
HD: healthy donors, TP: typical progressors, AIDS: HIV patients with AIDS, LTNP: long term non progressors.
ap-values were calculated for each SNP comparing the genotypes of LTNP population with the other groups using Fisher’s exact test (p<0.05 were considered
significant, ns, not significant).
bFalse discovery rate (FDR) correction for multiple testing (alpha = 0.1 were considered significant, ns, not significant).
https://doi.org/10.1371/journal.pone.0220459.t002
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these protective genotypes (p-values in Table 3). This suggests that viral replication limited
to this threshold value for many years may also be a marker of a profound and stable LTNP
status.
Allelic frequencies of HLA-A and -B in the Spanish LTNP cohort
LTNP and HD were typed for HLA class I. Most HLA alleles were not significantly different
between the LTNP and the control group. From those with significant differences, several
alleles seemed to favor the LTNP condition, as their allelic frequencies were significantly
higher in LTNP than in HD (Fig 2); these included HLA-B57, followed by HLA-B27, -B52,
-A03 and -B39. In contrast, HLA-B18 was markedly less frequent in the LTNP population,
as well as HLA-A24, -B08 and -A29, and thus appeared to be detrimental for LTNP status.
Stratification of the LTNP into subcategories was undertaken for most relevant alleles. Given
the high number of alleles for these two HLA loci, a very low number of patients was left in
most subcategories and precluded statistical analysis. Still, the strongest favorable factor
HLA-B57, together with -B52, -B27 and -A03, as well as the strongest unfavorable factor
HLA-B18, together with -A24 and -B08, were significantly enriched in LTNP subcategories
(Table 4). Interestingly, when the frequency of the HLA allele in the LTNP subcategories was
above 10% and amenable to analysis, it showed again an inverse correlation of HLA-B57 and
HLA-A03 protective alleles with VL (Fig 1C), as was the case for the favorable HCP5 and
CCR2 SNP.
When the HLA-B alleles were classified according to their mutually exclusive bw4 or bw6
public epitopes [30], a highly significantly greater percentage of bw4 in homozygosity was
observed in the LTNP compared with HD (Table 5), confirming these alleles as protective fac-
tors for the LTNP status. The converse association of bw6/bw6 homozygosity with risk for the
LTNP condition was also as strong, and both extended to most LTNP subcategories (Tables 4
and 5). As before, favorable bw4/bw4 showed a mild inverse correlation with VL while unfa-
vorable bw6/bw6 genotype showed a mild direct correlation with VL within Spanish LTNP
subcategories (Fig 1C).
Fig 1. Genotype frequencies among subpopulations of LTNP as a function of viral load. The frequencies of the indicated
SNP or CCR5-Δ32 genotypes (B) or HLA genotypes (C) relative to the total number of individuals are plotted for the LTNP
subcategories that are graphically depicted (A): ExLTNP, patients who were LTNP for 10 years but thereafter failed to fulfill
any of the inclusion criteria; LTNP-N, viremic non controller LTNP, VL>50–10,000; LTNP-C, controllers, VL<2,000 copies/
mL; EC, elite controllers, undetectable VL. Displayed are relevant SNP and HLA genotypes with a frequency in the LTNP
subcategories above 15%, indicating those that are more frequent (filled symbols) or less frequent (open symbols) in the overall
LTNP population than in HD, according to Table 3 and Fig 2.
https://doi.org/10.1371/journal.pone.0220459.g001
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Overview of genetics and LTNP status in the Spanish HIV cohorts
The 9 genotypes and alleles that are associated with LTNP status as well as those 5 unfavor-
able ones are listed in Table 4 and roughly ranked according to the intensity of the effect and
the statistical significance. Interestingly, when analyzed as individuals concerning protective
and risk factors, Spanish LTNP patients clearly stood up in comparison with HD. Almost
70% of LTNP patients had at least one HLA protective allele, and this rose to 87% when
protective SNP were also considered. In contrast, only 22% of the LTNP had a detrimental
allele (Fig 3). Fractions of HD controls having protective or risk alleles were very similar, for
reference.
Notably, the mean number of protective minus risk HLA alleles and SNPs in individual
Spanish healthy donors was balanced (0.74 protective– 0.62 risk to give a 0.12 balance per
person, or an average of 0.12 protective HLA alleles and SNPs per healthy person). In sharp
contrast, the mean was 12 times more marked for individual Spanish LTNP patients (1.66 pro-
tective– 0.23 risk to give an average of 1.43 protective HLA alleles and SNPs per LTNP patient),
Table 3. Genotype distribution of selected SNP, which have specific alleles associated with protection or with disease progression, in distinct subcategories of HIV
LTNP patients and in healthy donors.
SNP Group (n) Genotype distribution p-valuea FDRb
n % n % n %
HCP5 3'UTR (T/G) TT TG GG HD AIDS TP HD AIDS TP
rs2395029 HD (254) 245 96.5 9 3.5 0 0 - -
AIDS (55) 51 92.7 4 7.3 0 0 ns - ns -
TP (213) 191 89.6 22 10.4 0 0 0.0045 ns - 0.022 ns -
ExLTNP (32) 25 78.1 7 21.9 0 0 <10−3 ns ns 0.005 ns ns
LTNP-N (64) 53 82.8 11 17.2 0 0 <10−3 ns ns 0.005 ns ns
LTNP-C (79) 60 75.9 19 24.1 0 0 <10−6 0.0112 0.004 <10−4 0.044 0.022
EC (32) 22 68.8 10 31.3 0 0 <10−5 <10−2 0.003 <10−4 0.024 0.02
CCR2-V64I (G/A) GG GA AA
rs1799864 HD (262) 220 84.0 40 15.3 2 0.8 - -
AIDS (55) 44 80.0 10 18.2 1 1.8 ns - ns -
TP (212) 163 76.9 46 21.7 3 1.4 ns ns - ns ns -
ExLTNP (33) 26 78.8 6 18.2 1 3.0 ns ns ns ns ns ns
LTNP-N (64) 46 71.9 16 25.0 2 3.1 0.0471 ns ns ns ns ns
LTNP-C (79) 51 64.6 26 32.9 2 2.5 <10−3 ns ns 0.005 ns ns
EC (32) 20 62.5 12 37.5 0 0 0.0203 ns ns 0.066 ns ns
5'HLA-C (C/T) CC CT TT
rs9264942 AIDS (55) 16 29.1 22 40.0 17 31.9 - - -
TP (212) 41 19.3 104 49.1 67 31.6 - ns - - ns
ExLTNP (33) 10 30.3 18 54.5 5 15.2 - ns ns - ns ns
LTNP-N (63) 18 28.6 36 57.1 9 14.3 - ns 0.015 - ns 0.054
LTNP-C (78) 20 25.6 45 57.7 13 16.7 - ns 0.033 - ns 0.099
EC (32) 8 25.0 17 53.1 7 21.9 - ns ns - ns ns
HD: healthy donors; TP: typical progressors; AIDS: HIV patients with AIDS; LTNP: long term non progressors; ExLTNP: patients who were LTNP for 10 years but
thereafter failed to fulfill any of the inclusion criteria; LTNP-N: viremic LTNP with VL >10,000 copies/ml; LTNP-C: LTNP with VL <2,000 copies/ml; EC: elite
controllers with undetectable VL.
ap-values were calculated for each SNP comparing the genotypes of LTNP population with the other groups using Fisher’s exact test (p<0.05 were considered
significant, ns, not significant).
bFalse discovery rate (FDR) correction for multiple testing (alpha = 0.1 were considered significant, ns, not significant).
https://doi.org/10.1371/journal.pone.0220459.t003
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Table 4. Summary and statistics for differences in frequencies of the 16 genotypes and alleles associated with protection or disease progression described in this
report. Statistics apply to comparisons among distinct subcategories of Spanish LTNP patients, and with other groups of Spanish HIV patients and healthy donors.
SNP / HLA allele Groupa p-valuea FDRb
HD AIDS TP HD AIDS TP
P1a HLA-B57 LTNP (128) <10−7 - - <2.3x10-6 - -
ExLTNP (32) 1.0x10-4 - - <5.3x10-4 - -
LTNP-N (64) 1.0x10-4 - - <5.3x10-4 - -
LTNP-C (79) 1.0x10-4 - - <5.3x10-4 - -
EC (32) 1.0x10-4 - - <5.3x10-4 - -
P2 HCP5 3'UTR LTNP (128) <10−7 2.0x10-2 4.0x10-3 <2.3x10-6 3.0x10-2 8.9x10-3
rs2395029 (TG) ExLTNP (32) 6.0x10-4 ns ns 2.3x10-3 ns ns
LTNP-N (64) 4.0x10-4 ns ns 1.6x10-3 ns ns
LTNP-C (79) <10−7 1.0x10-2 4.0x10-3 <2.3x10-6 1.7x10-2 8.9x10-3
EC (32) <10−5 6.0x10-3 3.0x10-3 1.7x10-4 1.2x10-2 7.4x10-3
P3 HLA bw4/bw4 LTNP (128) 1.0x10-4 - - <5.3x10-4 - -
ExLTNP (32) 4.9x10-2 - - ns - -
LTNP-N (64) 1.6x10-3 - - 5.5x10-3 - -
LTNP-C (79) 1.0x10-4 - - <5.3x10-4 - -
EC (32) 1.7x10-3 - - 5.6x10-3 - -
P4 HLA-B52 LTNP (128) 2.0x10-3 - - 5.8x10-3 - -
ExLTNP (32) 1.0x10-2 - - 1.7x10-2 - -
LTNP-N (64) 2.9x10-2 - - 4.1x10-2 - -
LTNP-C (79) 2.1x10-2 - - 3.1x10-2 - -
P5 HLA-B27 LTNP (128) 2.0x10-3 - - 5.8x10-3 - -
LTNP-N (64) 2.0x10-4 - - 9.9x10-4 - -
LTNP-C (79) 1.5x10-2 - - 2.4x10-2 - -
P6 CCR2-V64I LTNP (129) 5.0x10-3 ns ns 1.1x10-2 ns ns
rs1799864 (GA/AA) LTNP-N (64) 3.0x10-2 ns ns 4.1x10-2 ns ns
LTNP-C (79) 4.0x10-4 ns 4.0x10-2 1.6x10-3 ns 5.0x10-2
EC (32) 6.0x10-3 ns ns 1.2x10-2 ns ns
P7 5'HLA-C LTNP (128) - 3.0x10-2 2.0x10-3 - 4.1x10-2 5.8x10-3
rs9264942 (CC/CT) LTNP-N (63) - 4.0x10-2 6.0x10-3 - 5.0x10-2 1.2x10-2
LTNP-C (78) - ns 1.0x10-2 - ns 1.7x10-2
P8 HLA-A03 LTNP (125) 1.0x10-2 - - 1.7x10-2 - -
LTNP-C (75) 1.0x10-2 - - 1.7x10-2 - -
EC (31) 3.0x10-3 - - 7.4x10-3 - -
P9 HLA-B39 c LTNP (128) 2.0x10-2 - - 3.0x10-2 - -
ExLTNP (32) 1.0x10-2 - - 1.7x10-2 - -
R1a HLA bw6/bw6 LTNP (128) 1.0x10-4 - - <5.3x10-4 - -
LTNP-N (64) 1.0x10-4 - - 5.3x10-4 - -
LTNP-C (79) 1.0x10-4 - - <5.3x10-4 - -
EC (32) 3.4x10-2 - - 4.5x10-2 - -
R2 HLA-B18 LTNP (128) 9.0x10-4 - - 3.3x10-3 - -
LTNP-N (64) 4.7x10-2 - - ns - -
LTNP-C (79) 3.0x10-4 - - 1.4x10-3 - -
EC (32) 3.7x10-2 - - 4.8x10-2 - -
R3 HLA-A24 LTNP (125) 2.5x10-3 - - 6.9x10-3 - -
LTNP-N (61) 1.3x10-2 - - 2.1x10-2 - -
LTNP-C (75) 2.6x10-3 - - 6.9x10-3 - -
(Continued)
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clearly indicating that LTNP is a population that has successfully undergone selection under
the selective pressure of the HIV epidemics.
Discussion
Several host genetic factors have been associated with HIV-1 disease progression in different
cohorts of LTNP, typical progressors or rapid progressors, when compared with HIV seroneg-
ative individuals [1–25]. The present study aims to investigate the role of genetic factors in a
large (n = 130) Spanish cohort of LTNP. However, the LTNP are a heterogeneous population
consisting of HIV-1 infected individuals showing different phenotypes regarding their
capacity to control viral replication. In this regard, the analysis has been extended to a consci-
entious stratification of LTNP, according to their VL, into elite controllers (EC), controllers
(LTNP-C), viremic non-controller LTNP (LTNP-N) and individuals losing the LTNP status
over time (ExLTNP).
Our analysis of the Spanish HIV-1 LTNP cohort and control healthy and infected popula-
tions, altogether representing 846 individuals, reveals 14 significant genetic factors. Nine of
them are more frequent in the LTNP population, and thus qualify as factors that contribute
to disease control and to LTNP status; in rough order of decreasing protective potency and
statistical power these are the following alleles or genotypes: HLA-B57, HCP5 TG rs2395029
SNP, HLA bw4/bw4 (p<0.0001, see individual details and summary in Table 4), HLA-B52,
HLA-B27, CCR2 GA/AA rs1799864 SNP (p<0.01,), 5’HLA-C CC/CT rs9264942 SNP,
HLA-A03 and HLA-B39 (0.01<p<0.05). Protective alleles/genotypes range each in frequency
among the LTNP population from 7% to 30%, supporting the notion that a large proportion
of the LTNP phenotype may be determined by accumulation of favorable genetic traits, rather
by a single strongly protective factor. Conversely, 5 genetic factors are less frequently found
in LTNP and appear to represent factors favoring disease progression; in rough order of
decreasing risk and statistical power these are the following alleles or genotypes: HLA bw6/
bw6, HLA-B18 (p<0.001), HLA-A24, HLA-B08, (p<0.01) and HLA-A29(p<0.05).
Two out of the 14 factors reported in Table 4 are described for the first time to our knowl-
edge in firm association with any type of HIV susceptibility to infection or disease progression
and, specifically, in association with the LTNP condition. Both are unfavorable HLA alleles,
HLA-B08 and -A29. In addition, another 3 factors that have been found associated with other
HIV conditions are described here for the first time in association with LTNP, including the
protective HLA-B39 and the risk factors HLA-B18 and -A24. Furthermore, the positive associ-
ation with LTNP of two more alleles, HLA-A03 and HLA-B52, for which very limited evidence
is published, is confirmed with the Spanish LTNP cohort. In the natural history of HIV
Table 4. (Continued)
SNP / HLA allele Groupa p-valuea FDRb
HD AIDS TP HD AIDS TP
R4 HLA-B08 LTNP (128) 3.6x10-3 - - 8.6x10-3 - -
LTNP-C (79) 2.4x10-2 - - 3.5x10-2 - -
R5 HLA-A29 LTNP (125) 1.1x10-2 - - 1.8x10-2 - -
aGenotypes or alleles are labelled P for ‘protection’ or R for ‘risk’ depending on whether their frequency is higher or lower in the indicated LTNP population.
respectively. and roughly numerically ordered from most protective and with the highest statistical power. P1. and from most risky and with the highest statistical
significance. R1.
b Only statistics for significant differences are listed (p<0.05); ns, not significant.
c Novel genetic factors described in this report in association with LTNP condition are framed.
https://doi.org/10.1371/journal.pone.0220459.t004
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infection, several HLA class I alleles have been associated consistently with HIV progression,
especially HLA-B alleles [10, 12, 14, 22, 31–34], and notably, we identify here novel HLA-B as
well as HLA-A alleles. Identification of several new genetic associations when compared with
studies on a geographically close population as the French cohort [35] stresses the importance
of assembling and studying such cohorts of patients that control HIV infection, in spite of the
scarcity of such patients. It also reveals the importance of thorough studies on novel cohorts
such as the Spanish one reported here. Among other factors, one possible reason for the
Fig 2. Comparison of the frequencies of HLA-A and HLA-B individuals between LTNP and healthy donor populations. HD,
n = 448 donors for HLA-A and HLA-B; LTNP, n = 125 patients for HLA-A and 128 patients for HLA-B. Statistically significant
differences are marked with asterisks (�, p<0.05; ��, p<0.01; ����, p<0.0001) and detailed in the text inset. Relevant frequencies for
HD vs. LTNP are: HLA-A03 (17 vs. 28%), HLA-A24 (17 vs 6.4%), HLA-A29 (17 vs. 8.0%), HLA-B8 (16 vs. 6.3%), HLA-B18 (11 vs
2.3%), HLA-B27 (7.4 vs. 17%), HLA-B39 (2.2 vs. 7.0%), HLA-B52 (2.2 vs. 8.6%) and HLA-B57 (4.2 vs. 30%).
https://doi.org/10.1371/journal.pone.0220459.g002
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novelty of our data may relate to the high proportion of intravenous drug users among the
Spanish LTNP compared with the majority of men who have sex with men (MSM) included in
the French LTNP cohort.
The novel detrimental associations of HLA-B08 and HLA-A29 with maintenance of the
LTNP status have little precedent in the literature. HLA-B08 within a common Western haplo-
type is frequently associated with fast progression of HIV disease, rapid CD4 T lymphocyte
decline in adults and with increased mother to infant transmission [32,36,37], but the associa-
tion has rarely been individually ascribed to HLA-B08. For HLA-A29 only a non-significant
trend has been reported [38]. This negative association may interestingly be related to the poor
recognition by A29-restricted T lymphocyte clones of viral sequence variants [39]. The large
Spanish LTNP cohort data thus presents solid evidence for the first time on the negative asso-
ciation of these two HLA alleles with the LTNP status.
Table 5. Frequency comparison of HLA bw4 and bw6 allele groups between HD and LTNP subcategories.
Group (n) Genotype distribution p-valuesa FDRb
n % n % n % bw4/bw4 bw6/bw6 bw4/bw4 bw6/bw6
HLA-B bw4/bw4 bw4/bw6 bw6/bw6
HD (421) 69 16.4 239 56.8 113 26.8 - - - -
LTNP (128) 45 35.2 71 55.5 12 9.4 1.1x10-5 2.0x10-5 1.2x10-4 1.0x10-4
ExLTNP (32) 10 31.3 17 53.1 5 15.6 0.049 ns ns ns
LTNP-N (64) 22 34.4 38 59.4 4 6.3 0.002 1.2x10-4 0.003 2.4x10-4
LTNP-C (79) 29 36.7 44 55.7 6 7.6 8.8x10-5 8.4x10-5 2.1x10-4 2.2x10-4
EC (32) 13 40.6 16 50 3 9.4 0.002 0.034 0.003 0.042
HD: healthy donors; TP: typical progressors; AIDS: HIV patients with AIDS; LTNP: long term non progressors; ExLTNP: patients who were LTNP for 10 years but
thereafter failed to fulfill any of the inclusion criteria; LTNP-N: viremic LTNP with VL >10.000 copies/ml; LTNP-C: LTNP with VL <2.000 copies/ml; EC: elite
controllers with undetectable VL.
aThe presence of bw4/bw4 or bw6/bw6 genotypes in different categories of LTNP subcategories compared with healthy donors (HD) was calculated using Fisher’s exact
test (p<0.05 were considered statistically significant; ns. not significant)
bFalse discovery rate (FDR) correction for multiple testing (alpha = 0.1 were considered significant. ns. not significant).
https://doi.org/10.1371/journal.pone.0220459.t005
Fig 3. Individuals with a minimum of one protective or one risk factor for maintaining LTNP status: Frequency
comparison between HD and LTNP. From top to bottom, the percentage of healthy controls and LTNP patients is
indicated that have at least one protective HLA allele, at least one protective HLA allele or SNP factor, or at least one
HLA risk allele, as listed in Table 4. ����, p< 0.0001. OR (95% confidence interval): 0.19 (0.12–0.30); 0.17 (0.09–0.31);
3.8 (2.4–6.1), respectively, from top to bottom. Stratification into LTNP subcategories did not provide additional
information, as they were very homogeneous; p value was also<0.0001 for all comparisons between HD and each
subcategory.
https://doi.org/10.1371/journal.pone.0220459.g003
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Concerning the three HLA alleles previously reported only in HIV patients other than
LTNP, the effect of HLA-B39, which is identified here as a protective allele for the Spanish
LTNP cohort, to our knowledge for the first time in association with LTNP, appears to depend
on the study, the geographical area or the HIV-infected population. HLA-B39 was described
as a risk allele in smaller populations of Argentinian HIV+ subjects [40] and of Indian serodis-
cordant couples [41], while, more in line with our results, as an allele associated with lower VL
in Zambian HIV infected patients [42]. The second allele associated in this cohort for the first
time with LTNP, HLA-A24, is described here as an unfavorable allele for the LTNP condition,
and it was also early associated with rapid CD4 T lymphocyte decline [36] and with suscepti-
bility in adults [43], promoting selection of cytotoxic T-lymphocyte escape variants in Japan
[44, 45]. Whether the detrimental role of HLA-A24 for LTNP described here in the Spanish
population is related to T-lymphocyte escape also in LTNP patients is currently unknown and
warrants investigation. Finally, HLA-B18 was the strongest and most significant detrimental
factor for the Spanish LTNP population. This HLA allele has been widely studied in HIV
infected populations other than LTNP, and its favorable [38, 41] or risk [40, 46] contribution
to diverse aspects of HIV disease is variable and at least seems to depend on the virus clade.
Further, HLA-A03 has been described in one report in association with French LTNP [35].
This early observation of positive association of HLA-A03 with LTNP is now confirmed with
our larger and stricter Spanish LTNP cohort. Otherwise, A03 has also occasionally been associ-
ated with populations of HIV-infected patients other than LTNP [37, 47]. As for HLA-A03, we
also describe a significant association of the HLA-B52 allele with delayed disease progression
in the Spanish cohort of LTNP patients, confirming an international HIV controllers study
[22] and a single earlier report weakly associating HLA-B52 with non-progression in a small
Brazilian cohort of HIV-1 infected individuals [48].
Out of the 14 factors identified here in positive or negative association with Spanish LTNP,
the remaining 7 factors were previously established, and our data are confirmatory. Previous
studies have associated low HIV-1 viremia and prolonged survival with HLA-B57 [7, 10] and
HLA-B27 [35] in HIV LTNP patients, and it is assumed that this is due to the antigen presenta-
tion by these alleles of conserved viral epitopes contributing to viral fitness. LTNP are also
characterized by the SNP rs2395029 located at HCP5 [18–21, 23], which is in tight linkage dis-
equilibrium with the HLA-B�5701 allele [13]. The fact that these HLA-B alleles display the
public HLA epitope bw4 is thought to underlie the previously described and here confirmed
positive role of bw4/bw4 homozygosity [14] and the converse negative role of the bw6/bw6
genotype. Interestingly, when considering HLA supertypes [49], the LTNP-associated protec-
tive HLA alleles described here clustered together in some HLA supertypes (A03, B7, B27, B58
and B62 supertypes), and segregated away from the supertypes of risk alleles (A1, A24 and B44
supertypes). As the supertypes are based on HLA antigen presentation function to cytotoxic
CD8+ T lymphocytes, this could possibly underlie the functional mechanism for their selective
association in HIV-1 infection.
The present study confirms the strong protective effect for Spanish LTNP of HCP5 3’UTR
TG rs2395029, CCR2 GA/AA rs1799864 and 5’HLA-C CC/CT rs9264942 SNPs.
When LTNP were stratified, gradual increases of the frequencies of favorable HCP5,
HLA-B57, HLA-A03, CCR2 and bw4/bw4 alleles and genotypes were concomitantly observed
with increasing HIV-1 control capacity, peaking at LTNP-C and EC populations, confirming a
trend previously assumed for some of them in other studies that analyzed a very limited num-
ber of LTNP patients [50]. Conversely, the strongly unfavorable bw6/bw6 genotype shows a
mild inverse correlation with control of VL. However, this study shows that there is no such
correlation of low VL with protective 5’HLA-C, as published [51], nor with CCR5 Δ32 deletion,
and questions including these two SNP as markers for reduced VL [50]. While the CCR5 Δ32
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deletion has extensively been confirmed to contribute to preventing initial HIV infection [1],
these data may suggest that, once infection is established in patients, it does not contribute to
maintaining a profound LTNP status as strongly as HCP5, HLA-B57, -A03, CCR2, or bw4/
bw4 genotypes may do.
The classification of HIV-1 infected patients based on clinical data includes LTNP, typical
progressors and rapid progressors. However, this classification can be enriched incorporating
the VL measurement to define a more realistic description of the LTNP status with the subcat-
egories included in the present study, i.e. EC-LTNP, LTNP-C, LTNP-N and ExLTNP. The
genetic factors influencing the LTNP status have widely been studied, even from a genome-
wide perspective [18–21]. However, the control of HIV-1 replication and the delayed disease
progression simultaneously observed in EC-LTNP and LTNP-C have been poorly character-
ized. In this regard, the present study provides new clues about the effect of known factors
influencing control and resistance to HIV-1 such as HCP5, CCR2, HLA-B57 and -A03 in
EC-LTNP and LTNP-C compared with the rest of LTNP. On the other hand, well-docu-
mented genetic factors associated to LTNP status such as CCR5 rs333 or 5’HLA-C do not seem
to have any additive effect in the EC-LTNP or LTNP-C condition with respect to the rest of
LTNP. Further studies are required to discern whether the EC-LTNP and LTNP-C statuses
can be considered as an accumulation of several factors previously associated with EC or
LTNP or as the presence of specific unknown associations with the simultaneous observation
of both phenotypes.
The fact that with new cohorts like the large multicentric and stratified Spanish ones it is
still possible to identify significant associations of the LTNP with 5 new HLA alleles (one pro-
tective and 4 detrimental for the LTNP condition) underscores the strong influence of HLA on
viral control. It is still open whether especially the most significant unfavorable HLA-B18 allele
could play a direct functional effect on control of HIV and in long-term stability of infected
LTNP patients.
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